Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Checkpoint CD47 expression in classical Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Doing less, accomplishing more for childhood ALL: response

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  5. TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Checkpoint CD47 expression in classical Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The EHA Research Roadmap: Malignant Lymphoid Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Patients with chronic lymphocytic leukaemia (CLL) have an increased risk of new malignancies. However, limited data have been published about the impact of CLL treatment on this risk. Here we followed a Danish population-based cohort of CLL patients for risks of new malignancies. Patients in the Danish CLL registry (2008-2017) were included. Up to 50 CLL-free matched comparators were identified. First-line treatment was categorized into four groups; bendamustine, chlorambucil, fludarabine or other. Patients were followed from CLL diagnosis for individual types of malignancy. Adjusted hazard ratios (HR) for new malignancies and 95% confidence intervals (95% CI) were calculated. Overall, 4286 CLL patients and 214 150 controls developed 594 and 20 565 new malignancies respectively. Risk of new malignancies was increased for CLL patients. Chemotherapy treatment was registered for 1064 (25%) patients with CLL. Chemotherapy was associated with increased HR (1·51, 95% CI: 1·3-1·8) of any new malignancy. Specifically, fludarabine was associated with an increased risk of myelodysplastic syndrome (MDS) (HR 4·93, 95% CI: 1·2-19·8). Patients with CLL are at increased risk of other haematological and solid malignancies compared to the general population. Chemotherapy exposure is associated with increased risk of second malignancies and fludarabine is associated with increased risk of MDS.

OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind193
Udgave nummer2
Sider (fra-til)339-345
Antal sider7
ISSN0007-1048
DOI
StatusUdgivet - apr. 2021

Bibliografisk note

© 2021 British Society for Haematology and John Wiley & Sons Ltd.

ID: 62113273